Skip Nav Destination
Issues
1 October 2021
-
Cover Image
Cover Image
Cancer prevention is the best approach for improving survival from cancers; however, there currently are no methods developed to prevent pancreatic cancer in high risk subjects. The majority of pancreatic cancers arise from histologic lesions called pancreatic intraepithelial neoplasias or PanINs. In this study starting on page 933, Smith and colleagues studied the effects of a cancer vaccine, PAS, on prevention of pancreatic cancer and PanIN progression in a transgenic mouse model of pancreatic cancer. Vaccination of mice with PAS from 3 months until 8 months of age resulted in decreased PanIN progression and decreased incidence of pancreatic cancer. By altering the pancreas microenvironment, PAS renders it less carcinogenic. The cover image shows high grade PanINs and loss of normal pancreas architecture in the untreated mice (left) and preservation of normal pancreas acinar cells and lower grade PanINs in the pancreas of a PAS-vaccinated mouse (right). - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1940-6207
EISSN 1940-6215
Highlights from the Literature
Commentary
Rethinking Cervical Cancer Screening in Brazil Post COVID-19: A Global Opportunity to Adopt Higher Impact Strategies
Ana Ribeiro; Flávia Corrêa; Arn Migowski; Aline Leal; Sandro Martins; Tainá Raiol; Carla P. Marques; Katia L. Torres; Akiva P. Novetsky; Jenna Z. Marcus; Nicolas Wentzensen; Mark Schiffman; Ana Cecilia Rodriguez; Julia C. Gage
Research Brief
Research Articles
Lipidomic Profiles of Plasma Exosomes Identify Candidate Biomarkers for Early Detection of Hepatocellular Carcinoma in Patients with Cirrhosis
Jessica I. Sanchez; Jingjing Jiao; Suet-Ying Kwan; Lucas Veillon; Marc O. Warmoes; Lin Tan; Mobolaji Odewole; Nicole E. Rich; Peng Wei; Philip L. Lorenzi; Amit G. Singal; Laura Beretta
Preventive Anti-inflammatory Diet to Reduce Gastrointestinal Inflammation in Familial Adenomatous Polyposis Patients: A Prospective Pilot Study
Antonino Belfiore; Chiara Maura Ciniselli; Stefano Signoroni; Manuela Gariboldi; Andrea Mancini; Licia Rivoltini; Daniele Morelli; Enzo Masci; Eleonora Bruno; Alessandra Macciotta; Maria Teresa Ricci; Elena Daveri; Laura Cattaneo; Giuliana Gargano; Giovanni Apolone; Massimo Milione; Paolo Verderio; Patrizia Pasanisi; Marco Vitellaro
Letters to the Editor
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.